Antibody Drug Conjugates (ADC) are an emerging class of drugs that combine antibodies and a drug payload. The antibody cargoes the drug payload to specific targeted cells improving both safety and efficacy. To date that are 8 FDA approved ADC drugs all for oncology application using small molecule drugs. Although these ADCs with small molecules encompass superior efficacy and safety than non-targeted small molecule drugs, it is increasingly evident that they lose efficacy due to the same multi-drug resistance by the cancer cells. In this project, we are exploring the synthesis and evaluation of larger molecule cyclical peptide toxin drugs that cancer cells find more challenging to develop resistance to. Traditionally, these cyclical peptide toxins are rarely used for oncology application due to a variety of systemic toxicity; however, by utilizing the ADC platform, this new class of toxins may be an important class of anti-cancer drug class to unlock.
iProgen Biotech Inc
Professional, scientific and technical services
University of British Columbia
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.